115 related articles for article (PubMed ID: 2503383)
1. Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Boomsma F; Ausema L; Hakvoort-Cammel FG; Oosterom R; Man in't Veld AJ; Krenning EP; Hahlen K; Schalekamp MA
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1045-52. PubMed ID: 2503383
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
3. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
[TBL] [Abstract][Full Text] [Related]
5. Plasma dopa and catecholamines in the diagnosis and follow-up of children with neuroblastoma.
Alvarado CS; Faraj BA; Kim TH; Camp VM; Bain RP; Ragab AH
Am J Pediatr Hematol Oncol; 1985; 7(3):221-7. PubMed ID: 3934994
[TBL] [Abstract][Full Text] [Related]
6. 3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
Ikeda H; Matsuyama S; Suzuki N; Takahashi A; Kuroiwa M
Hypertens Res; 1995 Jun; 18 Suppl 1():S209-10. PubMed ID: 8529065
[TBL] [Abstract][Full Text] [Related]
7. Determination of aromatic-L-amino acid decarboxylase in human plasma.
Boomsma F; van der Hoorn FA; Schalekamp MA
Clin Chim Acta; 1986 Sep; 159(2):173-83. PubMed ID: 3769207
[TBL] [Abstract][Full Text] [Related]
8. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
Berthold F; Hunneman DH; Harms D; Käser H; Zieschang J
Eur J Cancer; 1992; 28A(12):1950-4. PubMed ID: 1419287
[TBL] [Abstract][Full Text] [Related]
9. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
Simon T; Hero B; Hunneman DH; Berthold F
Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669
[TBL] [Abstract][Full Text] [Related]
10. 3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma.
Ikeda H; Suzuki N; Takahashi A; Kuroiwa M; Matsuyama S
Pediatr Hematol Oncol; 1996; 13(1):21-32. PubMed ID: 8718500
[TBL] [Abstract][Full Text] [Related]
11. Determination of urinary vanillactic acid and plasma dihydroxyphenylalanine as markers of non-secreting neuroblastoma by high-performance liquid chromatography with electrochemical detection.
Jouve J; Bakri D; Herault J; Muh JP
J Chromatogr; 1991 Jul; 567(2):331-41. PubMed ID: 1939466
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of catecholamine biosynthesis by carbidopa and metyrosine in neuroblastoma.
Anton AH; Crumrine RS; Stern RC; Izant RJ
Pediatr Pharmacol (New York); 1983; 3(2):107-17. PubMed ID: 6425794
[TBL] [Abstract][Full Text] [Related]
13. DOPA metabolism in neuroblastoma.
Helson L; Johnson GA; Smith R
Med Pediatr Oncol; 1980; 8(4):317-22. PubMed ID: 6779102
[TBL] [Abstract][Full Text] [Related]
14. Determination of 3,4-dihydroxyphenylalanine (DOPA) in plasma and cerebrospinal fluid by high performance liquid chromatography with electrochemical detection.
Boomsma F; van der Hoorn FA; Man in 't Veld AJ; Schalekamp MA
Clin Chim Acta; 1988 Nov; 178(1):59-69. PubMed ID: 3147824
[TBL] [Abstract][Full Text] [Related]
15. Catecholamine metabolism in neuroblastoma.
LaBrosse EH; Comoy E; Bohuon C; Zucker JM; Schweisguth O
J Natl Cancer Inst; 1976 Sep; 57(3):633-8. PubMed ID: 10450
[TBL] [Abstract][Full Text] [Related]
16. Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations.
Pappan KL; Kennedy AD; Magoulas PL; Hanchard NA; Sun Q; Elsea SH
Pediatr Neurol; 2017 Oct; 75():66-72. PubMed ID: 28823629
[TBL] [Abstract][Full Text] [Related]
17. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma.
Atwal PS; Donti TR; Cardon AL; Bacino CA; Sun Q; Emrick L; Reid Sutton V; Elsea SH
Mol Genet Metab; 2015; 115(2-3):91-4. PubMed ID: 25956449
[TBL] [Abstract][Full Text] [Related]
18. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology.
Hyland K; Clayton PT
Clin Chem; 1992 Dec; 38(12):2405-10. PubMed ID: 1281049
[TBL] [Abstract][Full Text] [Related]
19. Presence of endogenous inhibitor of aromatic L-amino acid decarboxylase in monkey serum.
Rahman MK; Togari A; Kojima K; Takahashi K; Nagatsu T
Mol Cell Biochem; 1984 Aug; 63(1):53-8. PubMed ID: 6333583
[TBL] [Abstract][Full Text] [Related]
20. Suppression of norepinephrine secretion by dopamine in children with neuroblastoma: evidence for precursor inhibition in catecholamine pathway.
Sato T; Minami S; Igarashi N; Miyagawa K
Endocrinol Jpn; 1989 Aug; 36(4):595-603. PubMed ID: 2583066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
